Immune-cell numbers predict response to combination immunotherapy in melanoma

(University of California - San Francisco) Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco researchers joined by physicians from UCSF Health.